First-in-class therapies for enhancing tissue repair and regeneration


Seattle, WA


Series A


Acquired (by Amgen, Inc.)

Rodeo Therapeutics Corporation focused on developing small-molecule therapies that increase tissue levels of prostaglandin PGE2. Preclinical studies have shown that increasing PGE2 through modulation of a prostaglandin-degrading enzyme (15-PGDH) protects against colitis and idiopathic pulmonary fibrosis (IPF), accelerates hematopoietic stem cell reconstitution following bone marrow transplant, and promotes liver regeneration in a variety of animal models.

Rodeo Therapeutics’ scientific approach is based on research conducted by world-renowned scientists at Case Western Reserve University and the University of Texas Southwestern Medical Center.

Stanton L. Gerson, MD
Joseph Ready, PhD
Sanford Markowitz, MD, PhD